← Back to Analyst Consensus 
CLDX Buy
Celldex Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 21
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Next Earnings
Nov 11, 2026 (16 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 2, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 23, 2026 | Leerink Partners | maintain | Outperform → Outperform | — | 51% |
| Sep 23, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Sep 22, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 22, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Sep 10, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Aug 7, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Aug 7, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 29, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 22, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 22, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Jul 22, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Jul 22, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jul 20, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jun 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 10, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| May 13, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| May 8, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Apr 20, 2026 | Barclays | upgrade | Underweight → Overweight | — | 53% |
| Mar 2, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Feb 26, 2026 | Stifel | reiterate | Buy → Buy | $68 | 53% |
| Dec 17, 2025 | Barclays | maintain | Underweight → Underweight | $24 | 53% |
| Nov 11, 2025 | Barclays | maintain | Underweight → Underweight | $21 | 53% |
| Oct 21, 2025 | Mizuho | initiate | — → Outperform | $48 | 52% |
| Oct 13, 2025 | Barclays | initiate | — → Underweight | $25 | 53% |
| Sep 17, 2025 | Canaccord Genuity | maintain | Buy → Buy | $62 | 48% |
| Aug 20, 2025 | Wells Fargo | maintain | Overweight → Overweight | $38 | 54% |
| Aug 20, 2025 | Citigroup | maintain | Buy → Buy | $48 | 54% |
| Aug 20, 2025 | Canaccord Genuity | maintain | Buy → Buy | $62 | 48% |
| Aug 20, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $42 | 44% |
| Jun 16, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
| Jun 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $50 | 44% |
| May 9, 2025 | UBS | maintain | Buy → Buy | $38 | 54% |
| May 9, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $31 | 54% |
| May 9, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $43 | 54% |
| May 9, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $50 | 44% |
| May 6, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Apr 28, 2025 | Canaccord Genuity | initiate | — → Buy | $64 | 48% |
| Mar 20, 2025 | Morgan Stanley | initiate | — → Overweight | $46 | 54% |
| Mar 3, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $36 | 54% |
| Mar 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Feb 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Feb 13, 2025 | UBS | initiate | — → Buy | $44 | 54% |
| Jan 2, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $67 | 50% |
| Dec 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Dec 19, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Nov 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Nov 7, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Oct 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $80 | 44% |
| Aug 12, 2024 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $37 | 54% |
Price Target Trend
May 7, 2026 Latest: $63.07 Oct 25, 2026
EPS Estimates
0y $-4.12
Lo: $-4.33 Hi: $-3.71
10 analysts ▲6
0q $-1.01
Lo: $-1.07 Hi: $-0.94
10 analysts ▲6
+1y $-4.25
Lo: $-5.00 Hi: $-3.26
10 analysts +1q $-1.01
Lo: $-1.12 Hi: $-0.87
10 analysts ▲5
Cross-Platform Signals
No cross-platform signals in the last 90 days